Zomig Side Effects
Generic name: zolmitriptan
Note: This document contains side effect information about zolmitriptan. Some of the dosage forms listed on this page may not apply to the brand name Zomig.
Some side effects of Zomig may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to zolmitriptan: oral tablet, oral tablet disintegrating
Other dosage forms:
Get emergency medical help if you have any of these signs of an allergic reaction while taking zolmitriptan (the active ingredient contained in Zomig) hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using zolmitriptan and call your doctor at once if you have a serious side effect such as:
feeling of pain or tightness in your jaw, neck, or throat;
chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden severe headache, confusion, problems with vision, speech, or balance;
fast or pounding heartbeats, dizziness;
sudden and severe stomach pain and bloody diarrhea;
numbness or tingling and a pale or blue-colored appearance in your fingers or toes; or
(if you are also taking an antidepressant) -- agitation, hallucinations, fever, fast heart rate, overactive reflexes, nausea, vomiting, diarrhea, loss of coordination, fainting.
Less serious side effects of zolmitriptan may include:
pressure or heavy feeling in any part of your body;
dry mouth, upset stomach;
feeling of pain or pressure in your neck or throat;
drowsiness, weakness; or
warmth, redness, or mild tingling under your skin.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to zolmitriptan: nasal spray, oral tablet, oral tablet disintegrating
Cardiovascular side effects including acute myocardial infarction, arrhythmias, hypertension, and syncope have been reported infrequently. Bradycardia, extrasystoles, postural hypotension, QT prolongation, tachycardia, and thrombophlebitis have rarely been reported.
Most of the serious cardiac events which have been reported occurred in patients with risk factors predicative of coronary artery disease.
In a study of patients with liver dysfunction, 7 out of 27 patients experienced 20 to 80 mm Hg elevations in systolic and/or diastolic blood pressure after a 10 mg dose of zolmitriptan.
Nervous system side effects (11% to 21%) including dizziness (6% to 10%), somnolence (5% to 8%), and vertigo (up to 2%) have been reported. Agitation, anxiety, depression, emotional lability, and insomnia have also been reported infrequently. Akathisia, amnesia, apathy, ataxia, dystonia, euphoria, hallucinations, cerebral ischemia, hyperkinesia, hypotonia, hypertonia, and irritability have been reported rarely. Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events including fatalities have been reported in patients treated with 5-HT1 agonists.
Regarding the cerebrovascular events reported in patients treated with 5-HT1 agonists, in a number of cases the cerebrovascular events may have been the primary event, whose symptoms were mistaken for a migraine.
Other side effects including pain and pressure sensations have been reported (13% to 22%). These sensations have included chest pain/tightness/pressure and/or heaviness (2% to 4%), neck/throat/jaw pain/tightness/pressure (4% to 10%), heaviness other than the chest or neck (1% to 5%), pain from a specified location (2% to 3%), and other pressure/tightness/heaviness (2%). Atypical sensations (12% to 18%) including hypoesthesia (1% to 2%), paresthesia (5% to 9%), and warm/cold sensations (5% to 7%) have been reported. Hyperesthesia has been reported infrequently. Asthenia (3% to 9%), palpitations (up to 2%), myalgia (1% to 2%), myasthenia (up to 2%) and drug-induced headache have also been reported. Otic changes including hyperacusis, ear pain, parosmia, and tinnitus have been reported infrequently.
Gastrointestinal ischemic events may present as bloody diarrhea or abdominal pain.
Gastrointestinal side effects (11% to 16%) including dry mouth (3% to 5%), dyspepsia (1% to 3%), dysphagia (up to 2%), and nausea (4% to 9%) have been reported. Increase in appetite, tongue edema, esophagitis, gastroenteritis, liver function abnormality, and thirst have been reported infrequently. Anorexia, constipation, gastritis, hematemesis, pancreatitis, melena, and ulcer have been reported rarely. Gastrointestinal ischemic events including splenic infarction, ischemic colitis, and gastrointestinal infarction or necrosis have been reported very rarely.
General side effects including allergic reactions, chills, facial edema, fever, malaise, and photosensitivity have been reported infrequently.
Several adverse effects (mostly mild and transient) are dose related, including paresthesia; sensation of heaviness or tightness in the chest, neck, jaw, and throat; dizziness; somnolence; and possibly asthenia, and nausea.
Hematologic side effects including ecchymosis have been reported infrequently. Cyanosis, thrombocytopenia, eosinophilia, and leukopenia have been reported rarely.
Metabolic side effects including edema have been reported infrequently. Hyperglycemia, and increased alkaline phosphatase have been reported rarely.
Musculoskeletal side effects including back pain, leg cramps, and tenosynovitis have been reported infrequently. Arthritis, tetany, myalgia, and twitching have been reported rarely.
Respiratory side effects including bronchitis, bronchospasm, epistaxis, hiccup, laryngitis, and yawn have been reported infrequently. Apnea and voice alteration have been reported rarely.
Hypersensitivity side effects including anaphylaxis and anaphylactoid reaction have been reported.
Ocular side effects including dry eye and eye pain have been reported infrequently. Diplopia and lacrimation have been reported rarely.
Genitourinary side effects including hematuria, cystitis, polyuria, urinary frequency, and urinary urgency have been reported infrequently. Miscarriage and dysmenorrhea have been reported rarely.
Dermatologic side effects including sweating (up to 3%) have been reported. Pruritus, rash, and urticaria have been reported infrequently.
More Zomig resources
- Zomig Prescribing Information (FDA)
- Zomig Consumer Overview
- Zomig Monograph (AHFS DI)
- Zomig Advanced Consumer (Micromedex) - Includes Dosage Information
- Zomig MedFacts Consumer Leaflet (Wolters Kluwer)
- Zolmitriptan Professional Patient Advice (Wolters Kluwer)
- Zolmitriptan Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.